Agency | $2,600,000 | (Aug 29, 2024)
Pryzm | $2,000,000 | (Aug 29, 2024)
Melodi Health | $10,750,000 | (Aug 29, 2024)
Certified by Founder
Lodge
ImpriMed, Inc.
start up
United States
- Mountain View, California
- 20/12/2023
- Series A
- $23,000,000
ImpriMed provides cutting-edge personalized medicine easily accessible for pets with blood cancer diseases. ImpriMed’s key product, Personalized Prediction Profile, has been used by board-certified veterinary oncologists, helping over 5,000 dogs with lymphoma and leukemia. With ImpriMed’s services, veterinarians make their treatment decisions quickly and with confidence. This innovative approach to cancer care has been published in a scientific journal and presented at major conferences and is supported by over 350 veterinary oncologists at 200+ specialty hospitals in the US.
- Industry Biotechnology Research
- Website https://www.imprimedicine.com/
- LinkedIn https://www.linkedin.com/company/imprimed-inc/about/
Ampersand Energy | $2,000,000 | (Aug 29, 2024)
Pangeam Inc. | $4,250,000 | (Aug 29, 2024)
Moveo.AI | $2,600,000 | (Aug 29, 2024)
Parry Labs | $80,000,000 | (Aug 29, 2024)
MIRIS | $26,000,000 | (Aug 29, 2024)
Ancilia Biosciences | $4,200,000 | (Aug 29, 2024)
OpusClip | $30,000,000 | (Aug 29, 2024)
Inventive AI | $4,000,000 | (Aug 29, 2024)
Piramidal (YC W24) | $6,000,000 | (Aug 29, 2024)